PARIS--(BUSINESS WIRE)--Ipsen (Paris:IPN) (Euronext:FR0010259150) announced today that the 4-month sustained release formulation of Decapeptyl®, originated from the Group’s internal research, is being tested in a phase III clinical trial. This new formulation, aimed at improving patients’ quality of life, is based on Ipsen’s proprietary drug delivery system technology and uses the Group’s advanced drug delivery platform. This development is part of the life-cycle management strategy for the products of Ipsen research and development pipeline.
